We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.31% less ownership

Funds ownership: 50.87% → 49.55% (-1.3%)

7% less funds holding

Funds holding: 115 → 107 (-8)

25% less capital invested

Capital invested by funds: $152M → $113M (-$38.5M)

34% less call options, than puts

Call options by funds: $109K | Put options by funds: $164K

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

Holders
107
Holders Change
-8
Holders Change %
-6.96%
% of All Funds
2.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
33
Reduced
21
Closed
17
Calls
$109K
Puts
$164K
Net Calls
-$55K
Net Calls Change
-$265K

Top Buyers

1
BlackRock
BlackRock
New York
+$1.33M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$556K
3
State Street
State Street
Massachusetts
+$417K
4
Two Sigma Investments
Two Sigma Investments
New York
+$147K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$124K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$1.45M
2
DWM
Destination Wealth Management
California
-$1.42M
3
Deutsche Bank
Deutsche Bank
Germany
-$1M
4
MHP
Manatuck Hill Partners
Connecticut
-$747K
5
LCM
Laurion Capital Management
New York
-$472K
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
51
Family Management
New York
$65K +$17.3K +8,572 +31%
JG
52
Jefferies Group
New York
$65K +$72.5K +36,030 New
Susquehanna International Group
53
Susquehanna International Group
Pennsylvania
$63K +$7.94K +3,944 +13%
CS
54
Credit Suisse
Switzerland
$62K -$25.2K -12,508 -27%
Citigroup
55
Citigroup
New York
$59K +$3.48K +1,726 +6%
UBS Group
56
UBS Group
Switzerland
$58K +$29.9K +14,859 +87%
USAA
57
United Services Automobile Association
Texas
$52K – – –
State Board of Administration of Florida Retirement System
58
State Board of Administration of Florida Retirement System
Florida
$47K – – –
RIM
59
Regent Investment Management
Kentucky
$46K – – –
Baird Financial Group
60
Baird Financial Group
Wisconsin
$44K – – –
BDS
61
Banco de Sabadell
Florida
$41K – – –
TRCT
62
Tower Research Capital (TRC)
New York
$39K +$44.2K +21,968 New
Teacher Retirement System of Texas
63
Teacher Retirement System of Texas
Texas
$37K -$6.97K -3,461 -14%
JP Morgan Chase
64
JP Morgan Chase
New York
$37K +$1.72K +855 +4%
CFA
65
Carroll Financial Associates
North Carolina
$35K – – –
Wolverine Trading
66
Wolverine Trading
Illinois
$33K – – –
Simplex Trading
67
Simplex Trading
Illinois
$33K +$15.6K +7,748 +72%
BA
68
BKS Advisors
Michigan
$31K – – –
ECM
69
Elgethun Capital Management
South Dakota
$31K – – –
Legal & General Group
70
Legal & General Group
United Kingdom
$31K +$465 +231 +1%
Carson Wealth (CWM LLC)
71
Carson Wealth (CWM LLC)
Nebraska
$31K +$35K +17,374 New
RAM
72
Riggs Asset Management
Pennsylvania
$27K -$922 -458 -3%
AB
73
Amalgamated Bank
New York
$26K +$3.09K +1,535 +12%
Barclays
74
Barclays
United Kingdom
$25K -$143K -70,956 -84%
Principal Financial Group
75
Principal Financial Group
Iowa
$25K +$1.14K +565 +4%
1 2
3
4 5

LCTX Hedge Fund Activity: Q2 2018 in Review

107 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2018, worth a combined $113M — down 25% from $152M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of LCTX and 9 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 33 added.

The largest buyer was BlackRock, adding an estimated $1.33M. The largest seller was Renaissance Technologies, cutting an estimated $1.45M.

  • 107 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2018, down from 115 in Q1 2018.
  • Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2018, down 25% quarter-over-quarter.
  • 9 funds opened new Lineage Cell Therapeutics positions in Q2 2018 and 17 closed out, a net change of -8 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.33M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2018 was Renaissance Technologies, an estimated $1.45M sold.

Based on aggregated 13F filings for Q2 2018.